ATE306556T1 - Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung. - Google Patents

Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.

Info

Publication number
ATE306556T1
ATE306556T1 AT99901639T AT99901639T ATE306556T1 AT E306556 T1 ATE306556 T1 AT E306556T1 AT 99901639 T AT99901639 T AT 99901639T AT 99901639 T AT99901639 T AT 99901639T AT E306556 T1 ATE306556 T1 AT E306556T1
Authority
AT
Austria
Prior art keywords
reducing conditions
pharmaceutical compositions
compositions containing
containing same
compounds sensitive
Prior art date
Application number
AT99901639T
Other languages
German (de)
English (en)
Inventor
Gerardo Byk
Catherine Dubertret
Bruno Pitard
Daniel Scherman
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9801065A external-priority patent/FR2774394B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE306556T1 publication Critical patent/ATE306556T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT99901639T 1998-01-30 1999-01-28 Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung. ATE306556T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9801065A FR2774394B1 (fr) 1998-01-30 1998-01-30 Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
US7702698P 1998-03-06 1998-03-06
PCT/FR1999/000162 WO1999038821A2 (fr) 1998-01-30 1999-01-28 Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications

Publications (1)

Publication Number Publication Date
ATE306556T1 true ATE306556T1 (de) 2005-10-15

Family

ID=26234096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99901639T ATE306556T1 (de) 1998-01-30 1999-01-28 Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.

Country Status (14)

Country Link
US (1) US6521252B1 (enExample)
EP (1) EP1049793B1 (enExample)
JP (1) JP2002501762A (enExample)
KR (1) KR20010081924A (enExample)
CN (1) CN1289371A (enExample)
AT (1) ATE306556T1 (enExample)
AU (1) AU759197B2 (enExample)
BR (1) BR9907269A (enExample)
CA (1) CA2318512C (enExample)
DE (1) DE69927669T2 (enExample)
HU (1) HUP0101393A3 (enExample)
IL (1) IL137247A0 (enExample)
NO (1) NO20003880L (enExample)
WO (1) WO1999038821A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
CA2424619C (en) * 2000-10-04 2010-05-18 Kyowa Hakko Kogyo Co., Ltd. Method for coating fine particles with lipid membrane
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
FR2921369B1 (fr) * 2007-09-25 2014-07-11 Pf Medicament Nouveau procede de preparation de derives (poly) aminoalkylaminoacetamide d'epipodophyllotoxine,utiles pour leurs applications en therapeutique comme agent anticancereux.
GB0720486D0 (en) * 2007-10-19 2007-11-28 Univ Edinburgh Cationic lipids
US9765022B2 (en) * 2013-02-28 2017-09-19 Tufts University Disulfide compounds for delivery of pharmaceutical agents
US11433128B2 (en) * 2017-04-07 2022-09-06 Tianxin Wang Cell surface anchoring antigen conjugates to treat cancer
CN111918668A (zh) * 2018-02-16 2020-11-10 王天欣 治疗肿瘤细胞和癌症的方法和药剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
WO1991014696A1 (en) 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
KR19990022597A (ko) 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 티오양이온성 지질, 제약조성물 및 그 사용 방법
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP0945138A1 (en) 1997-12-04 1999-09-29 Université Louis Pasteur de Strasbourg Transfection particles
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances

Also Published As

Publication number Publication date
HUP0101393A3 (en) 2004-10-28
BR9907269A (pt) 2001-04-03
DE69927669D1 (de) 2006-02-23
HUP0101393A1 (hu) 2001-08-28
CN1289371A (zh) 2001-03-28
AU759197B2 (en) 2003-04-10
KR20010081924A (ko) 2001-08-29
EP1049793A2 (fr) 2000-11-08
AU4384300A (en) 2001-04-05
JP2002501762A (ja) 2002-01-22
WO1999038821A2 (fr) 1999-08-05
CA2318512C (fr) 2009-10-13
EP1049793B1 (fr) 2005-10-12
NO20003880D0 (no) 2000-07-28
IL137247A0 (en) 2001-07-24
WO1999038821A3 (fr) 1999-09-23
US6521252B1 (en) 2003-02-18
CA2318512A1 (fr) 1999-08-05
DE69927669T2 (de) 2006-07-20
NO20003880L (no) 2000-07-28

Similar Documents

Publication Publication Date Title
ATE313642T1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
YU83600A (sh) Adenozin a3 receptorski modulatori
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
DE69942610D1 (de) Die bindung von integrinen zu deren rezeptoren verhindernde verbindungen
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
ID24730A (id) Senyawa-senyawa heterosiklik untuk penghambatan sekresi asam lambung, proses pembuatan dan komposisi-komposisi farmasinya
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
PT892849E (pt) Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico
BR9810372A (pt) Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
ATE306556T1 (de) Für reduzierende bedingungen empfindliche transfektions-verbindungen, pharmazeutische zusammensezungen die diese enthalten und deren verwendung.
BR0010349B1 (pt) derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
DE69516066D1 (de) Flüssigkristallzusammensetzung und Zellen, die diese enthalten
ES2126652T3 (es) Metodo de citodiagnostico utilizando la alstonina como marcador selectivo y kit de diagnostico conteniendo dicho marcador.
HUP0102413A1 (hu) Vektorok nukleinsavak bevitelére, ezeket tartalmazó készítmények és alkalmazásuk
DE69928524D1 (de) Biologisch aktive zusammensetzung
TR200100801T2 (tr) Benzoilguanidin türevleri, imalatlarına yönelik yöntemler, ilaç yapımında kullanımı
NO20001812D0 (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav
DE3671444D1 (de) Biologisch aktive substanz, girolline genannt, extrahiert aus dem schwamm pseudaxinyssa cantharella, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
DE69836096D1 (de) Anti-idiotypische monoklonale antikörper, deren verwendung zur aktiven immuntherapie bösartiger tumoren, und zusammensetzungen die diese enthalten
BR9915897A (pt) Agentes de transferência de ácidos nucleicos, composição, utilização de um agente de transferência e processos de tratamento de corpo humano ou animal e de transferência de ácidos nucleicos.
MX9801920A (es) Composicion farmaceutica util para la transfeccion de acidos nucleicos y sus usos.
BR0115182A (pt) Composição de substância carreadora de produtos à base de papaìna e hialuronidase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties